Induction of permanent mixed chimerism and skin allograft tolerance across fully MHC-mismatched barriers by the additional myelosuppressive treatments in mice primed with allogeneic spleen cells followed by cyclophosphamide.
A pure method of drug (cyclophosphamide plus busulfan)-induced skin allograft tolerance in mice that can regularly overcome fully H-2-mismatched barriers in mice has been established. The components of the method are i.v. administration of 1 x 108 allogeneic spleen cells on day 0, i.p. injection of 200 mg/kg CP and 25 mg/kg busulfan on day 2, and i.v. injection of T cell-depleted 1 x 107 bone marrow cells from the same donor on day 3. Recipient B10 (H-2b; IE-) mice prepared with this conditioning developed donor-specific tolerance, and long-lasting survival of skin allografts was shown in almost of the recipient mice. In the tolerant B10 mice prepared with new conditioning, stable multilineage mixed chimerism was observed permanently, and IE-reactive Vbeta11+ T cells were reduced in periphery as seen in untreated B10.D2 (H-2d; IE+) mice. The specific tolerant state was confirmed by the specific abrogation against donor Ag in the assays of CTL activity and MLR and donor-specific acceptance in the second skin grafting. These results demonstrated that the limitation of standard protocol of cyclophosphamide-induced tolerance, which have been reported by us since 1984, can be overcome by the additional treatments with the myelosuppressive drug busulfan, followed by 1 x 107 T cell-depleted bone marrow cells. To our knowledge, this is the first report to induce allograft tolerance with a short course of the Ag plus immunosuppressive drug treatment without any kind of mAbs (pure drug-induced tolerance).
Tomita
Y
Y
Department of Cardiovascular Surgery, Kyushu University, Fukuoka, Japan. tomita@heart.med.kyushu-u.ac.jp
Yoshikawa
M
M
Zhang
Q W
QW
Shimizu
I
I
Okano
S
S
Iwai
T
T
Yasui
H
H
Nomoto
K
K
D000818:Animals; D001853:Bone Marrow / Q000187:drug effects / Q000276:immunology*; D016026:Bone Marrow Transplantation / Q000276:immunology / Q000401:mortality; D003520:Cyclophosphamide / Q000008:administration & dosage*; D003602:Cytotoxicity, Immunologic; D004351:Drug Resistance; D006085:Graft Survival / Q000235:genetics / Q000276:immunology; D006086:Graft vs Host Disease / Q000276:immunology; D006183:H-2 Antigens / Q000235:genetics / Q000276:immunology*; D006650:Histocompatibility Testing; D007108:Immune Tolerance / Q000187:drug effects / Q000235:genetics*; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D007962:Leukocytes / Q000276:immunology / Q000378:metabolism; D007959:Lymphocyte Culture Test, Mixed; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D011828:Radiation Chimera / Q000276:immunology*; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000097:blood; D016038:Skin Transplantation / Q000276:immunology*; D013045:Species Specificity; D013154:Spleen / Q000166:cytology / Q000276:immunology / Q000637:transplantation*; D013601:T-Lymphocytes / Q000187:drug effects; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D019172:Transplantation Conditioning
D006183:H-2 Antigens; D007166:Immunosuppressive Agents; D016693:Receptors, Antigen, T-Cell, alpha-beta; D003520:Cyclophosphamide